Growth factors in periodontal regeneration

Introduction:

Growth factors are polypeptide molecules released by cells in the inflamed area that regulate events in wound healing. These are naturally occurring proteins that regulate various aspects of cell growth and development acting locally or systemically. “Growth factor” is a general term to denote a class of polypeptide hormones that stimulate a wide variety of cellular events such as proliferation, chemotaxis, differentiation and production of extracellular-matrix proteins. Initially, growth factors were described as soluble molecules, but with present evidence it is clear that that the binding of growth factors to the extracellular matrix (ECM) is a major mechanism which regulates growth factor activity.

Growth factors are proteins that may act locally or systemically to affect the growth and function of cells in several ways. Exogenous growth factors can be used to supplement natural growth factors in wound healing which serves as basis for many upcoming regenerative therapies. In the following discussion we shall study in detail about various growth factors, their sources and target cells and their effects at cellular and molecular level.

Rationale of using growth factors in periodontal regeneration:

In general when injury occurs, a “well orchestrated” cell-cell and cell-extracellular matrix interaction is initiated which begins the healing process. A complex activity of various molecules including cytokines and growth factors begins in the inflamed area initiating extracellular matrix remodelling. Tissue repair studies conducted on animals provide evidence that key growth factors involved in wound healing include EGF, TGF-α and β, PDGF, acidic and basic FGF.

Various studies have shown that if one or more of the above chemical mediators are removed from the healing site, the process of healing is hampered. Every growth factor has specific role during development and healing, and identification of their exact mechanism of action and their affects on various cells is under research presently. The rationale for using the growth factors in periodontal regenerative therapy is based on knowledge of function of these molecules at the cellular and molecular level 1. To understand their role in periodontal regeneration, we must have the basic knowledge of these growth factors.

Classification of growth factors:

Growth factors and cytokines have historically been classified into ‘families’ based on their source cell type and apparent activity and/or impact on a given cell type, system, or tissue.  Following table describes various growth factors belonging to various growth factor families.  

The growth factor families

Growth factor family
Members
Platelet-Derived Growth Factor FamilyPDGF-AA
PDGF-BB
PDGF-AB
PDGF-CC
PDGF-DD
Vascular endothelial growth factor familyVascular endothelial growth factor-A (VEGF-A)
Vascular endothelial growth factor-B (VEGF-B)
Vascular endothelial growth factor-C (VEGF-C)
Vascular endothelial growth factor-D (VEGF-D)
Vascular endothelial growth factor-E (VEGF-E)
Vascular endothelial growth factor-F (VEGF-F)
Placenta-derived growth factor (PlGF)
Transforming growth factor beta superfamilyTGF-β
Inhibins
Activin
Anti-müllerian hormone
Bone morphogenetic protein
Decapentaplegic
Vg-1
Epidermal growth factor familyEpidermal Growth Factor
TGF-α
Schwannoma-derived growth factor
Heparin-binding EGF (HB-EGF)
Betacellulin
Epiregulin
Neuregulin (NRG) family
Fibroblast growth factor familyAcidic FGF (aFGF, FGF-1)
Basic FGF (bFGF, FGF-2)
Int-2 (FGF-3)
hst/KS3 (FGF-4)
FGF-5
FGF-6
Keratinocyte growth factor (FGF-7)
Androgen-induced growth factor (AIGF or FGF-8)
Glia activating factor (GAF or FGF-9)
Keratinocyte growth factor-2 (FGF-10)
FGFs 11–14
FGF-15
FGFs 16–19
FGF-20 (XFGF-20)
FGFs 21-23
The insulin familyInsulin-like growth factors I (IGF-I)
Insulin-like growth factors II (IGF-II)
Hepatocyte growth factor familyHepatocyte growth factor (HGF)
Macrophage-stimulating protein (MSP).
Colony-stimulating factors (CSF)IL-3
Macrophage-CSF (M-CSF)
Granulocyte-CSF (G-CSF)
Erythropoietin.
Neurotrophin FamilyNeurotrophic factor
Brain-derived neurotrophic factor (BDNF)
Neurotrophin-3 (NT-3)
NT-4
NT-5
NT-6

Evidence for role of growth factors in periodontal regeneration:

There is a lot of evidence available which shows regenerative potential of growth factors in periodontal regeneration. Local administration of PDGF to periodontal osseous defects leads to significant regeneration of bone, cementum, and periodontal ligament 2. In a dog study, Cho et al. 3 demonstrated that platelet- derived growth factor (PDGF) application with guided tissue regenerative therapy in critical size bone defects resulted in complete bone regeneration. Similar results were demonstrated by Park et al. 4 in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor.

Periodontal ligament cell proliferation and migration during healing is considered to be the major event during periodontal regeneration. It has been suggests that the Polypeptide growth factors PDGF, IL-1, and TGF-β are mediators of these cellular events in wound healing. One study investigated the effects of these growth factors on human periodontal ligament (PDL) cell mitogenesis, and the regulatory influences of TGF-β on the response to PDGF and IL-1. Results of the study demonstrated that PDGF-AA and PDGF-BB are major mitogens for human PDL cells in vitro, and supports a role for TGF-β as a regulator of the mitogenic response to PDGF in these cells 5. In a comparative study, response of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors was investigated. The migratory responses of PDL cells and gingival fibroblasts to platelet derived growth factor (PDGF), insulin like growth factor-I, -II (IGF-I, -II), epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) was evaluated. It was seen that both PDL cells and GF exhibited dose-dependent migratory responses when challenged with PDGF, IGF-I, IGF-II, EGF, and TGF-β. Authors concluded that PDL cell specific agents aid in periodontal regeneration 6.

In one study, a combination of platelet-derived growth factor (PDGF) and insulin-like growth factor one (IGF-1) was used in periodontitis-affected teeth in beagle dogs. The results showed that a continuous layer of osteoblasts lined the newly formed bone, and there was a dense cellular “front” at the coronal extent of the new bone. The results of the study suggested that application of the combination of PDGF and IGF-1 may enhance regeneration of the periodontal structures 7. A clinical trial evaluated a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in periodontal bone regeneration in patients with periodontal disease. An increase of 2.08 mm of new vertical bone height and 42.3% osseous defect fill in the HD-PDGF/IGF-I subjects was observed as compared to controls who demonstrated only 0.75 mm and 18.5% gains in new bone height and osseous fill, respectively 8.

It has been shown that fibroblast growth factors are strongly mitogenic to bone marrow stromal cells and are able to maintain the self-renewal of these cells in culture 9. Fibroblast growth factor-1 and fibroblast growth factor-2 in vitro stimulate osteoblast proliferation but do not increase collagen production or alkaline phosphatase in differentiated osteoblasts 10-11.

In the following paragraphs, we shall study in detail various well investigated growth factors and their potential application in periodontal regeneration.

Platelet- derived growth factor (PDGF):

Platelet- derived growth factor (PDGF) was originally purified from human platelets. Kohler and Lipton  (1974) 12 and Ross et  al. (1974) 13 discovered that the bioactive mediators released from platelets are the principal source of mitogenic activity present in serum, and is responsible for the growth of many cells in culture that are serum dependent. Recently PDGF has been found to be produced by various other cells, for example, monocytes, megakaryocytes, vascular endothelium, smooth muscle cells, and transformed ells 14-15. PDGF was shown to stimulate wound healing which resulted in its first therapeutic application, becaplermin (Regranex ®), a gel containing recombinant PDGF-B, which accelerates ulcer repair. Platelet- derived growth factor (PDGF) was the first growth factor to be evaluated in preclinical periodontal and peri-implant regenerative studies.

PDGF is a well characterized regulatory protein with an isoelectric point of 9.8 and a molecular weight of approximately 30,000 Da 16. The structure of the molecules has been described as two disulfide-bonded polypeptide chains that are encoded by two different genes, PDGF-A and PDGF-B, located on chromosomes 7 and 22, respectively 1, 17. Two new forms, PDGF-C and PGDF-D have been described recently 18. So, PDGF has 5 isoforms, PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD. Among these, 3 isoforms PDGF-AA, PDGF-AB and PDGF-BB have been extensively studied 2, 7, 19-22. Platelets synthesize a mixture of the three possible PDGF isoforms (70% AB, 20% BB, 10% AA) 23. They differ in their functional properties as well as in their secretory behaviors. PDGF-AA and PDGF-AB are rapidly secreted from the producer cell, whereas PDGF-BB remains to a large extent associated with the producer cell and relatively small amounts are secreted 21. PDGF acts on the target cells by binding to α and β receptors on their cell surfaces and in turn stimulates them. It has been reported that PDGF-AA and PDGF-AB are more rapidly secreted from the producer cell compared to PDGF-BB 21, and also PDGF-AB is found to have strong mitogenic effect on cells expressing both α and β receptors 17.

Actions of PDGF:

PDGF is a chemoattractant for fibroblasts, leukocytes and smooth muscle cells. It acts synergistically with IGF-1 promoting proteins synthesis and production of extracellular matrix. It has mitogenic effects on osteogenic cells, promoting their proliferation and migration in the healing area. It also promotes synthesis of fibronectin and types I, III and V collagen. It inhibits collagenase and plasminogen activator. PDGF up-regulates the expression of angiogenic molecules like vascular endothelial growth factor (VEGF)  and  hepatocyte growth factor, and also the proinflammatory  cytokine interleukin-6; thereby indirectly promoting periodontal regeneration. The recombinant human PDGF-BB (GEM2 IS) has received FDA clearance for use. The vehicle used for GEM2 IS is tricalcium phosphate which provides appropriate localization concentration of PDGF at the wound site for sufficient period of time, facilitating its desired affects during healing.

Literature review:

In vitro and in vivo studies have demonstrated that PDGF is a potent chemotactic and mitogenic factor for gingival and periodontal ligament fibroblasts, cementoblasts and osteoblasts 7, 24-26. It has been demonstrated that PDGF-BB applied to root surfaces increased proliferation of period of periodontal ligament cells, cementoblasts, osteoblasts, perivascular cells and endothelial cells 27.

Lynch et al. (1991) 28 treated 13 dogs with human recombinant PDGF-BB and PGF-I in methyl cellulose gel. At 5 weeks after surgery, histologic analysis demonstrated a significant increase in new bone and cementum formation in the growth factor treated sites over that in control sites. In another study, the effect of PDGF and IGF-I was evaluated on periodontal regeneration in vivo in a non human primate model. The results of the study demonstrated that PDGF and IGF stimulated regeneration of periodontal attachment in monkeys. After and weeks, the addition of growth factors stimulated regeneration of 50% of lost attachment while only 14% regeneration occurred in control sites which did not receive PDGF and IGF-I 29.

In an implant study on dog model, direct application of an rh PDGF/IGF mixture into implant sites produced a two to three times increase in the number of peri-implant spaces filled with bone as compared to initial readings 28. Another study demonstrated that bone density and bone-to-implant contact were increased twofold for the growth factor treated sites, as compared to the membrane alone or membranes combined with bone grafts 30.

The applications of PDGF in horizontal ridge augmentation procedures was evaluated in one study. Bilateral mandibular surgically created defects were treated with either beta-tricalcium phosphate (β−TCP) covered with a collagen membrane (CM) or a combination of β−TCP + CM + rhPDGF-BB, following a split-mouth design. The results of the study demonstrated that the group containing rhPDGF-BB showed better results in terms of mineralized tissue and total augmented area at 3 weeks 31. Encouraging results have been demonstrated for maxillary sinus floor augmentation procedure using anorganic bovine bone mineral combined with recombinant human platelet-derived growth factor BB 32.

Transforming Growth Factor α (TGF-α):

It belongs to the EGF family of cytokines. It is a mitogenic polypeptide and secreted protein, which is expressed by monocytes, keratinocytes, and various tumor cells. It has 80% homology with EGF and it binds to the cellular EGF receptor. EGF and TGF- α are equipotent at inducing in vitro endothelial cell proliferation and bind equally well to endothelial cell EGF receptor. It acts synergistically with TGF-β to stimulate anchorage-independent cell proliferation and produce a mitogenic response.

Transforming growth factorβ (TGF-β):

TGF- β or transforming growth factor‑β belongs to TGF- β superfamily, which has many multi-functional structurally related growth and differentiation factors associated to the inflammatory response. These factors play important role in apoptosis, angiogenesis, wound healing and fibrosis. TGF-β is a highly conserved dimeric polypeptide with a molecular weight of 2500 Da and consists of 2 amino acid chains linked together by disulfide bonds. It is found in highest concentration in bone and platelets. TGF‑β is encoded by three different genes TGF‑β1, TGF‑β2, and TGF‑β3. TGF-β1 contains 390 amino acids and TGF-β2 and TGF-β3 each contain 412 amino acids. It has been shown to increase the biosynthesis of type I collagen, fibronectin and osteocalcin, as well as bone matrix deposition and chemotaxis of osteoblast. On the other hand, it decreases synthesis of metalloproteinases and plasminogen activator. Receptors for TGF- β are transmembrane molecule containing a serine/threonine kinase domain referred to as Type-I and Type II and written as TbRI and TbRII respectively.

It can also modulate other growth factors such as PDGF, TGF-α, EGF and FGF possibly by altering their cellular response or by inducing their expression. TGF- β has a marked effect on ECM homeostasis, being an important mediator of fibroblast proliferation and ECM synthesis. It stimulates mesenchymal cells and inhibits epithelial cell proliferation. TGF- β1 has pro-fibrotic role which can be related to its role in gingival overgrowth. During healing process, it promotes collagen fiber deposition and causes fibrosis which can be related to gingival enlargement during inflammation. The precise role of TGF- β1 in the pathogenesis of periodontitis-induced gingival overgrowth is still unclear.

Actions of TGF-β:

Briefly, primary actions of TGF-β are,

  • It acts as an important factor for fibroblast migration and proleferation.
  • It has pleiotropic affects on cell proliferation, which can either stimulate or inhibit proliferation in different cell types and within the same cell type.
  • It promotes synthesis of collagenous matrix and regulates exttracellular matrix.
  • A weak mitogen for osteoblastic cells.
  • It may play an important role in immune regulation.

Literature review:

TGF-β plays a significant role in periodontal regeneration. However, very few periodontal regeneration studies using TGF-βs have been performed. The initial animal experiments done on dogs 33, 34 and sheeps 35 to evaluate the regenerative potential of TGF-β1 gave disappointing results. Other animal experiments demonstrated increased amount of bone healing adjacent to dental implants 36. TGF-β has synergistic effect with PDGF in stimulating gingival fibroblast and periodontal ligament cell proliferation.

A study done to measure the time-sequence response of RNA and protein synthesis to TGF-β1 by human periodontal ligament (HPDLF) and gingival (HGF) fibroblasts in culture showed that the effects of TGF-β1 on HPDLF and HGF were both time and dose dependent, with 10(-9) M TGF-β1 providing the best response of those concentrations tested 37.

Bone morphogenetic proteins:

BMPs belong to the transforming growth factor-β (TGF-β) superfamily, which consists of a group of related peptide growth factors. They have numerous cellular functions including development, morphogenesis, cell proliferation, apoptosis, and extracellular matrix synthesis. These proteins are synthesized as large precursor molecules which after dimerization are cleaved proteolytically at a consensus Arg-X-X-Arg site to generate mature dimers. Presently, more that 20 BMP’s have been identified which have been studied for their biological activity. Because, extensive research has been done on these proteins and the fact that these proteins may be potential candidates for newer periodontal regenerative techniques, a complete chapter has been dedicated to them. Detailed description of BMP’s is available in “Bone morphogenetic proteins”.

Fibroblast Growth Factors:

These are family of structurally related strongly heparin binding peptides that have been implicated in healing and regeneration. To date, twenty three distinct FGFs have been discovered, numbered consecutively from 1 to 23. All the FGFs have a central core of 140 amino acids that is highly homologous between different family members. The two best studied members, acidic FGF (a FGF) and basic FGF (b FGF), interact with the same cell surface receptor and thus share similar biologic activity, although b FGF usually exhibits 30- to 100-fold greater potency in vitro. Both FGF-1 and FGF-2 were initially isolated from bovine pituitary extracts based on their stimulation of [3H] thymidine incorporation in 3T3 fibroblasts 38, 39. They have been shown to stimulate mitogenesis and chemotaxis in periodontal ligament cells 40, 41.

To mediate their range of effects, fibroblast growth factor proteins signal via membrane-spanning tyrosine kinases (FGFR) and there are a wide variety of mechanisms for receptor regulation and availability. Atleast 4 FGF receptors have been identified and cloned from human CDNA. They have been named FGFR1, FGFR2, FGFR3 and FGFR4. They all have similar structure; an extracellular domain with 3 immunoglobulin like regions that binds FGF3, a transmembrane domain and a cytoplasmic domain that contains a tyrosine-specific protein kinase region. Their molecular weights vary from 95,000 to 150,000.

Fibroblast growth factor-1 (FGF-2)/acidic FGF:

FGF-1 has an isoelectric point range of 5.6-6.0 and a molecular weight of approximately 15,000 Da. It is a 155 amino acid protein. This protein functions as a modifier of endothelial cell migration and proliferation, as well as an angiogenic factor. It acts as a mitogen for a variety of cells. aFGF is considered to function in several important physiological and pathological processes, such as embryonic development, morphogenesis, angiogenesis and wound healing.

Fibroblast growth factor-2 (FGF-2)/ basic FGF:

FGF-2 has an isoelectric point of approximately 9.6 and a molecular weight in the range of 16,000-18,000 Da. Human FGF2 occurs in low molecular weight (LMW) and high molecular weight (HMW) isoforms. LMW FGF2 is primarily cytoplasmic and functions in an autocrine manner, whereas HMW FGF2s are nuclear and exert activities through an intracrine mechanism 42. Immunohistochemical analysis of tissues for bFGF often reveals bFGF in association with the extracellular matrix and in basement membranes attached to heparan sulfate. The binding of FGF-2 to the FGF receptor (FGFR) activates a signal transduction cascade, eventually stimulating cell proliferation and differentiation. This binding of FGFs to their tyrosine kinase-signaling receptors (FGFRs) requires heparan sulfate (HS). Heparan sulfate protects bFGF from proteolytic degradation 43. FGF-2 expressed by osteoblasts is generally more potent than FGF-1 44.

In periodontium, FGF-2 is present in the extracellular matrix, as well as in the cementum and can function as a local factor at the site 45. In inflamed periodontal tissues, bFGF has been identified in the gingival epithelium, inflammatory cells and connective tissue 46.

Know more………..

Is heparin/heparan sulfate (HS) necessaryfor FGF function?

Research done on FGF functioning has revealed that heparin/heparan sulfate (HS) is a part of the FGF/FGFR signaling complex. However, the importance of HS for FGF activity in vivo has remained controversial. A critical feature of the FGF binding to heparan sulfate is that it is central to FGF signaling. As is known for most other growth factors, FGFs signal by activating a receptor tyrosine kinase (RTK), which initiates a phosphorylation cascade within the cell that culminates in multiple cellular outcomes 47. FGF RTKs contain a heparan sulfate binding region. This is located just distal to the second Ig loop and is contained in all spliced forms of the RTKs. This region constitutes the minimal portion of the receptor that will bind FGF.

 

Actions of FGF:

Briefly actions of FGFs are as follows,

At cellular level:

  • FGFs are considered to be competence growth factors. A competence growth factor is one which stimulates resting cells in Go to enter the cell cycle in G1.
  • They have been associated with increased mitogenesis of cells.
  • It is found in association with the extracellular matrix in the basement membranes and is attached to heparan sulphate, which provides protection from degradation and allows it to maintain its biological potential.

During wound healing:

  • They play an important role during wound healing. The aFGF, bFGF and keratronocyte growth factor (KGF) are primary FGFs involved in wound healing.
  • They stimulate proliferation of most of the major cell types involved in wound healing including vascular endothelial cells, fibroblasts, keratinocytes and chondrocytes.
  • bFGF also stimulates epithelialisation, fibronectin, proteoglycan and collagen synthesis.
  • It has been shown that administration of bFGF at the time of wound closure not only significantly increases the breaking strength of the wound but also improves the quality of the scar 18.
  • FGF-2 stimulates periosteum derived cells in early stages of bone healing.

Angiogenesis:

  • FGF-2, in particular has the ability to induce all steps necessary for new blood vessel formation both in vivo and in vitro 18. It regulates the production of type I collagen and laminin by PDL cells. Laminin is one of the most important biological substances which is involved in angiogenesis 48.
  • FGF-1 stimulates endothelial cell proliferation which enhances new blood vessel proliferation in healing area.

Effect on PDL cells:

  • They have chemotactic and mitogenic effects on periodontal ligament cells.
  • Due to their overall effects, they play a vital role in the process of periodontal regeneration.

Literature review:

The effect of FGFs on osteoblast has been main focus of research. It has been shown that FGF-1 and FGF-2 stimulate cell proliferation but inhibit alkaline phosphatase (ALP) activity and reduce collagen type I (ColI) and osteocalcin (OC) expression 10, 11, 44, 49-51. Initial research demonstrated that bFGF and aFGF are stored in bone matrix and may be an important factor in regulating osteoblastic cells 52. In one study, the effects of recombinant human FGF-2 (rhFGF-2) on human neonatal calvaria osteoblastic cells was evaluated. The results of the study showed that the effects of FGF-2 are osteoblast differentiation stage specific and FGF-2 may modulate osteogenesis by acting at distinct stages of cell maturation. It was seen that in less mature cells, rhFGF-2 slightly stimulated cell growth and reduced the expression of osteoblast markers, whereas it induced osteocalcin production and matrix mineralization in more mature cells 53.

The expression of receptors for basic fibroblast growth factor on human periodontal ligament cells was investigated in one study which concluded that the responsiveness of PDL cells to bFGF is altered during the course of their culture due to change in the density of receptor on their surface. So, the density of FGFR expression might be a marker of the cytodifferentiation of PDL cells into mineralized tissue forming cells 54.

One study investigated the role of basic fibroblast growth factor (bFGF) in the wound healing and regeneration of periodontal tissues in surgically created 2-wall, 3-wall and furcation class II bone defects in beagle dogs and primates. Results of the study demonstrated that bFGF enhances the proliferative responses of human PDL cells, which express FGF receptor-1 and -2, but inhibits the induction of alkaline phosphatase activity and mineralized nodule formation by PDL cells. Hence, FGF-2 helps in regeneration of periodontal structures by inducing proliferation of PDL cells 55.

In a double blind controlled trial, the efficacy of the local application of recombinant human fibro-blast growth factor-2 (FGF-2) in periodontal regeneration was investigated. The trial included 253 adult patients with periodontitis. Modified Widman periodontal surgery was performed, during which 200 μL of the investigational formulation containing 0% (vehicle alone), 0.2%, 0.3%, or 0.4% FGF-2 was administered to 2-or 3-walled vertical bone defects. Sites with FGF-2 application showed significant superiority over vehicle alone for the percentage of bone fill at 36 wks after administration, and the percentage peaked in the 0.3% FGF-2 group. It was concluded that application of FGF-2 could be effectively used for periodontal regeneration 56.

Various molecules and their functions during different phases of wound healing 57

Wound healing phase
Growth factor
Secreted from
Functions
Inflammatory phasePDGFPlateletsIncreases chemotaxis of neutrophils and monocytes.
VEGFPlatelets
Leukocytes
Fibroblasts
Increase vascular permeability.
TGF-βPlatelets
Leukocytes
Fibroblasts
Increases chemotaxis of neutrophils and monocytes.
Autocrine expression.
Generation of additional cytokines (TNF-alpha, IL-1beta, PDGF and chemokines).
Proliferative phase
EGFMacrophages Mesenchymal cells
Platelets
Stimulates epithelial proliferation and migration.
KGF (FGF-7)Keratinocytes
Fibroblasts
Stimulates epithelial proliferation and migration
FGF-2Macrophages
Endothelial cells
Stimulates fibroblasts proliferation and ECM synthesis.
Increase chemotaxis, proliferation and differentiation of endothelial cells.
PDGFMacrophages
Endothelial cells
Stimulates fibroblasts proliferation and ECM synthesis.
Increase chemotaxis, proliferation and differentiation of endothelial cells.
VEGFMacrophagesIncreases chemotaxis of endothelial progenitor cells.
Stimulates endothelial cell proliferation.
TGF-βMacrophages
Leukocytes
Fibroblasts
Stimulates epithelial proliferation and migration.
Stimulates fibroblasts proliferation and ECM synthesis.
Inhibits proteases and enhances inhibitor production.
Bone remodelling and matrix synthesisBMPs 2-4OsteoblastsStimulates mesenchymal progenitor cell migration.
BMP-7OsteoblastsStimulates osteoblast and chondroblast differentiation.
FGF-2Macrophages, Endothelial cellsStimulates mesenchymal progenitor cell migration.
IGF-2Macrophages Fibroblasts Stimulates osteoblast proliferation and bone matrix synthesis.
PDGFMacrophagesStimulates differentiation of fibroblasts into myofibroblasts.
Stimulates proliferation of mesenchymal progenitor cells.
TGF-βFibroblasts
Osteoblasts
Induces endothelial cell and fibroblast apoptosis.
Induces differentiation of fibroblasts into myofibroblasts.
Stimulates chemotaxis and survival of osteoblasts.
VEGFMacrophagesChemotaxis of mesenchymal stem cells.
Aantiapoptotic effect on the bone-forming cells.
Angiogenesis promotion.
BMP: Bone morphgenetic protein
ECM: Extracellular matrix
EGF: Epidermal growth factor
FGF: Fibroblast growth factor
IGF: Insulin-like growth factor
KGF: Keratinocyte growth factor
PDGF: Platelet derived growth factor
TGF: Transforming growth factor
VEGF: Vascular endothelial growth factor

Insulin like growth factors (IGFs):

IGFs were first described in 1957 by Salmon and Daughaday 58. They are a family of mitogenic proteins that control growth, differentiation, and the maintenance of differentiated function in numerous tissues. These growth factors are single chain proteins that share 49% homology with pro-insulin 16. The IGF family includes three ligands (insulin, IGF-I, and IGF-II), their corresponding cell surface receptors (IR, IGF-IR, and IGF-IIR), and at least six IGF-binding proteins (IGFBPs). The six identified forms of IGFBPs are synthesized and secreted by a variety of cell types 59.

Two well described members of this group are IGF-1 and IGF-2 which are similar in structure and function but independently regulated 60. Both IGF-1 and IGF-2 are anabolic peptides with 65% amino acid sequence homology and similar biologic activities. However, synthesis of these factors is regulated and controlled in different manner 1. The precursor molecules of IGF-I and IGF-II have 195 and 156 amino acid sequence respectively which are proteolytically cleaved to release the biologically active monomeric proteins with 70 and 67 amino acids. IGFs are present in circulation as well as in tissue fluids in association with IGF binding proteins (IGFBPs), which bind IGFs with high affinity 59.

Insulin like growth factor-I (IGF-I):

IGF-1 is a 70-amino-acid protein with a molecular weight of 7649 Da and an isoelectric point of 8.4. It has endocrine, paracrine, and autocrine effects. It is mainly produced by the liver but virtually every tissue is able to secrete IGF-I for autocrine/paracrine purposes 61. It shares >60% homology with IGF-II and around 50% homology with proinsulin structures 62. Although, IGF-I binds to six forms of high affinity IGF binding proteins (IGFBPs 1 to 6), either promoting or inhibiting its actions; but majority of IGF-I actions are mediated through the union of IGF-I to its putative receptor, IGF-IR, a tyrosine kinase.

Actions of IGF-I:

Growth and development:

  • It plays a very important role in fetal growth and differentiation.
  • It has important role during central nervous system development where it acts as neuroprotector. It may promote proliferation and/or survival of oligodendrocytes and their precursors.
  • It has important role in cardiovascular system. It has been shown that IGF-I and its receptor are expressed in the myocardium and both aortic smooth muscle and endothelial cells 63, 64.
  • IGF-I plays important roles in T lymphocytes development and function. Specifically, it can increase the number of CD4+ CD8+ immature T cells in rat thymus and spleen 65, promotes T cell survival 66, proliferation, chemotaxis and maturation, and blocks spontaneous and induced programmed cell death 67.
  • IGF-I has been shown to play important role in liver regeneration. During liver regeneration, along with IL-6, TNF-α, HGF and TGF-α/EGF it supports hepatocyte proliferation and accelerates DNA synthesis 68, 69.

 Effects at cellular level:

The major effects of IGF-I on cells are,

  • It is a powerful chemoattractant of fibroblasts  and  it  leads  to  the  periodontal  regeneration  by stimulating the  formation  of mesenchymal tissues  including collagen,  bone  and  cementum 70.
  • It upregulates cementoblast  mitogenesis, phenotypic  gene  expression,  and mineralization 71.
  • IGF-I has demonstrated a capacity to increase bone cell mitoses and increase the deposition of matrix. PDGF and IGF have shown an ability to work together during the reparative stages of bone healing 2, 72.
Know more……….

Relationship between pituitary derived growth hormones (GH) and IGF-I:

The effects of pituitary derived GH are to a great extent mediated by the actions of insulin like growth factor-I (IGF-I). The GH axis is known to play a critical role in cell proliferation and IGF-I is an identified regulator of apoptosis in many tissues 73, 74. So, it has been hypothesised that growth hormone initiates cell differentiation and increases the production of IGF-I which then promotes cell division. This is also known as dual effector theory.

 

Role in wound healing:

Present evidence suggests that IGF-I is important factor involved during wound healing because it is mitogenic for keratinocytes 75 and is a potent chemotactic agent for vascular endothelial cells. IGF-1 expression is modulated during wound healing. Its levels are increases in healing site suggesting that its presence is requires for adequate wound healing 76, 77.

Effect of periodontal ligament cells:

In general IGF has been shown to increase fibroblast proliferation. One study demonstrated the mitogenic effects of IGF-I on periodontal ligament fibroblastic cells and concluded that a synergistic effect results from using a combination of PDGF-AB and IGF-1 78. Similarly, another study showed that IGF-I can stimulate the synthesis of DNA in periodontal ligament fibroblast, likely via binding to high affinity cell surface receptors 79.

Insulin like growth factor-II (IGF-II):

IGF-2, also known as multiplication stimulating activity (MSA) is a 67-amino-acid neutral peptide with a molecular weight of 7471 Da. IGF-II binds to IGF-II receptor (IGF-IIR), to IGF-IR and weakly to the insulin receptor (IR). It is not as potent as IGF-I. There is relatively less clinical research data available of IGF-II in relation to periodontal regeneration. The effect of IGF-II on the metabolism of gingival fibroblasts is still uncertain.

Epidermal growth factor (EGF):

The epidermal growth factor is a multifunctional cytokine involved in variety of functions including epithelial growth and differentiation, and wound healing. In 1986, Stanley Cohen received the Nobel Prize for his work elucidating the role of the Epidermal Growth Factor (EGF) in the regulation of cell growth and development 80. The epidermal growth factor family includes at least seven similar protein messages, such as transforming growth factor alpha and amphiregulin, and four receptors, collectively termed ErbB or HER receptors.

The epidermal growth factor is a small protein comprising of 53 amino acids. It is produced by epithelial cells, fibroblasts and many other cell types. It is found in membrane associated and soluble forms. The low molecular weight soluble EGF is generated through proteolysis of a large ~130,000 molecular weight transmembrane precursor. Both soluble and membrane forms of EGF are active. Its actions are activated with its attachment to the epidermal growth factor receptor (EGFR). This receptor induces cell differentiation and proliferation upon activation through the binding of one of its ligands.  The EGFR has 3 major regions:

  1. Extracellular domain which contains growth factor.
  2. Hydrophobic transmembrane domain
  3. Cytoplasmic domain which contains the tyrosine specific protein kinase.

Literature review:

In a study, the expression of epidermal growth factor (EGF) in normal and surgically wounded PDL tissues and its effect on chemotaxis and expression of osteoinductive and angiogenic factors in human PDL cells (HPDLCs) was investigated. It was observed that the levels of EGF and IL-1β were found to be upregulated in a PDL tissue-injured model of rat. The results of the study indicated that EGF is upregulated under inflammatory conditions which plays roles in the repair of wounded PDL tissue 81.

A study was done to understand the role of epidermal growth factor receptor (EGF-R) in periodontal ligament (PDL) fibroblasts on rat derived PDL cells and and ROS 17/2.8 cells (highly differentiated osteoblastic osteosarcoma cells). These cells were cultured and treated with transforming growth factor-alpha (TGF-alpha), EGF, dexamethasone (Dex) or a combination of EGF and Dex. Alkaline phosphatase (ALP) activity was then calculated as an indicator of mineralized tissue formation. It was observed that PDL fibroblastic cells express numerous EGF-R, but their number decreases during their differentiation into mineralized tissue-forming cells indicating that EGF-R may function in the stabilization of phenotype in PDL fibroblastic cells 82. Another study supported these findings 83.

Although, a lot of research work is going on EGF, but the effect of EGF on periodontal wound healing in vivo remains to be investigated.

Vascular endothelial growth factor (VEGF):

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and was first described as an essential growth factor for vascular endothelial cells. It is also known as vascular permeability factor (VPF). Originally, it was described as endothelial cell-specific mitogen 84.  

Sources:

  • Macrophages
  • Platelets
  • Keratinocytes
  • Tumor cells

VEGF is an important growth factor involved in functions such as bone formation 85, hematopoiesis 86, wound healing 87, and development 88. The VEGF family currently comprises seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and PlGF. All members have a common VEGF homology domain.

Actions:

  1. VEGF-A induces angiogenesis by following mechanisms,VEGF-A is chemotactic for macrophages and granulocytes.
    1. ↑ Migration of endothelial cells
    2. ↑ mitosis of endothelial cells
    3. ↑ Matrix metalloproteinase activity
    4. ↑ αvβ3 activity
    5. creation of blood vessel lumen
    6. creates fenestrations
  2. VEGF-A is chemotactic for macrophages and granulocytes.
  3. VEGF-A is involved in vasodilation (indirectly by NO release).
  4. VEGF-B is involved in embryonic angiogenesis.
  5. VEGF-D is needed for the development of lymphatic vasculature.
  6. PIGF is Important for Vasculogenesis.

Literature review:

Studies have been done to investigate the role of VEGF in periodontal health and disease. One study investigated the presence of VEGF in human periodontal tissue and gingival crevicular fluid (GCF) in periodontal health and disease. Levels of VEGF in GCF and saliva of diseased as well as healthy controls were measured. VEGF in tissue was localized by immunohistochemistry. This study reported that VEGF could be relevant to angiogenic processes in healthy as well as diseased periodontal tissue and that the periodontal status influences the salivary level of VEGF 89.

Another study investigated the role of VEGF in periodontal disease progression and the effect of periodontal therapy on VEGF concentrations in GCF. Study included a healthy (group 1), gingivitis (group 2), and chronic periodontitis (group 3) groups. A fourth group consisted of subjects from group 3, 8 weeks after treatment (scaling and root planing). GCF samples collected from each patient were quantified for VEGF levels using enzyme-linked immunosorbent assay (ELISA). Study concluded that VEGF levels in GCF increased from health to periodontitis, and periodontal treatment resulted in a reduction in their concentrations 90.

Few studies have been done to evaluate the effects of VEGF on periodontal ligament cell behaviour. One study investigated whether fibroblast growth factor (FGF-2) could induce vascular endothelial growth factor (VEGF)-A expression in periodontal ligament (PDL) cells and whether cell-to-cell interactions between PDL cells and endothelial cells could stimulate angiogenesis. Study concluded that FGF-2 induced VEGF-A expression in PDL cells and induced angiogenesis in combination with VEGF-A. The cell-to-cell interactions with PDL cells also facilitate angiogenesis 91.

Another study evaluate the effects of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) on the proliferation, migration, and adhesion of human periodontal ligament stem cells (PDLSC) in vitro. Human PDLSC were cultured in vitro using tissue culture method and were incubated with various concentrations of FGF-2 and VEGF. Study concluded that both FGF-2 and VEGF could simulate the proliferation of PDLSC in a dose dependent manner, and they had a synergistic effect. FGF-2 was more effective to promote the adhesive capacity of PDLSC compared with VEGF. VEGF could facilitate the migration of PDLSC to the wound side 92.

Colony-stimulating factors (CSF):

The CSFs act on stem cell leading to lineage specific differentiation. Stem cell factor (SCF) regulates differentiation of CD34+ stem cells whilst other factors modulate the synthesis of more specific cell types: erythropoietin (EPO) for red cells; granulocyte colony stimulating factor (G- CSF) for neutrophils; granulocyte-macrophage colony stimulating factor (GM-CSF) for macrophages and neutrophils; macrophage colony stimulating factor (M-CSF, also called colony-stimulating factor-1 (CSF-1)) for monocytes; and thrombopoietin (TPO) for megakaryocyte maturation and platelet synthesis. IL-3 is a CSF known as multi-CSF. It stimulates the formation of all non lymphocyte blood cells.

Conclusion:

In the above discussion we discussed various aspects of growth factors and their present research in periodontal regeneration. As discussed in previous sections, various studies have shown that growth factors may effectively promote periodontal regeneration. But, there are multiple problems associated with using growth factors for periodontal regeneration, mainly including,

  • Need for high local concentration.
  • Non-specific activity on different cell lineages in time and space.
  • Rapid loss of topically applied growth factors.

We are now working on development of techniques which may address these problems and provide us effective mechanism of delivering these growth factors in the area of periodontal regeneration. A detailed description of these techniques is available in “Tissue engineering in periodontal regeneration”.

WARNING

Any unauthorized use or reproduction of periobasics.com content for commercial or any purposes is strictly prohibited and constitutes copyright infringement liable to legal action.

References:

Please contact author for references

References:

Leave a Reply

You must be logged in to post a comment.